ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Regulus and Sanofi overhaul microRNA partnership

by Lisa M. Jarvis
November 9, 2018 | APPEARED IN VOLUME 96, ISSUE 45

 

Regulus Therapeutics has granted Sanofi an exclusive license for RG-012, a microRNA therapeutic in a Phase II study for a genetic kidney disease called Alport syndrome. Running low on cash, Regulus in July laid off 60% of its staff and paused recruitment for the RG-012 trial while it reconfigured its long-standing partnership with Sanofi. The French drug firm will pay roughly $7 million for full rights to RG-012 and reimburse Regulus for some activities.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment